SA113340642B1 - أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها - Google Patents
أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها Download PDFInfo
- Publication number
- SA113340642B1 SA113340642B1 SA113340642A SA113340642A SA113340642B1 SA 113340642 B1 SA113340642 B1 SA 113340642B1 SA 113340642 A SA113340642 A SA 113340642A SA 113340642 A SA113340642 A SA 113340642A SA 113340642 B1 SA113340642 B1 SA 113340642B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- الم
- definition
- humanized
- antibody
- arrangement
- Prior art date
Links
- 102000004472 Myostatin Human genes 0.000 title claims 3
- 108010056852 Myostatin Proteins 0.000 title claims 3
- 239000005557 antagonist Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 241001580017 Jana Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 238000009434 installation Methods 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 235000013372 meat Nutrition 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 claims 1
- 241000282994 Cervidae Species 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 241000989913 Gunnera petaloidea Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 241001554420 Ludia Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 241000235834 Myrina Species 0.000 claims 1
- 241000233803 Nypa Species 0.000 claims 1
- 235000005305 Nypa fruticans Nutrition 0.000 claims 1
- 241000036848 Porzana carolina Species 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 241001130469 Tila Species 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 108010014561 ovomucoid inhibitors Proteins 0.000 claims 1
- 239000005020 polyethylene terephthalate Substances 0.000 claims 1
- 229920000139 polyethylene terephthalate Polymers 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000000772 tip-enhanced Raman spectroscopy Methods 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 208000026062 Tissue disease Diseases 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
يوفر الكشف أجسام مضادة (antibodies) ضد GDF-8 متعادلة محسنة قادرة على الظهور عند مستويات عالية في خلايا العائل (host cells) مقارنة مع الأجسام المضادة ضد GDF-8 السابقة. يوفر أيضا طرق استخدام تركيبات (compositions) تشتمل على الأجسام المضادة (antibodies) هذه لزيادة كتلة أو قوة العضلة، ولمعالجة أو منع اضطرابات عضلية، اضطرابات عضلية عصبية، اضطرابات أيضية، اضطرابات نسيج دهني أو اضطرابات العظم. شكل 1(أ).
Claims (1)
- م عناصر الحماية -١ جسم مضاد «(antibody) أو جزء ارتباط مولد المضاد (antigen binding fragment) منه؛ الذي يربط بصفة خاصة 601-8؛ يشتمل الجسم المضاد (antibody) المذكور أو الجزء على: منطقة ثقيلة متغيرة (VH) للجسم المضاد (antibody) تشمل مناطق التحديد التكميلية (CDR) (complementarity determining regions) © الأولى» الثانية والثالثة من المنطقة VH المحددة بترتيب @amino acid من تعريف الترتيب رقم: std منطقة خفيفة متغيرة (V0) للجسم المضاد (antibody) تشمل مناطق التحديد التكميلية (CDR) (complementarity determining regions) الأولى» الثانية والثالثة من المنطقة VIL المحددة بترتيب @MINO acid من تعريف الترتيب رقم: 17 ؛ ٠ حيث تشتمل المنطقة VH المذكورة على leucine عند موقع amino acid المقابل للمتخلف رقم ١١ من تعريف الترتيب رقم: ££ .)٠١8 Rabat ads) "- الجسم المضاد (antibody) أو الجزء من عنصر الحماية ٠ حيث تشتمل 6081 VH على تعريف الترتيب رقم ٠١ أو تعريف الترتيب رقم: «Fv تشتمل VH CDR2 على تعريف الترتيب Vo رقم: ١١ أو تعريف الترتيب رقم: oY) تشتمل VH CDR3 على تعريف الترتيب رقم: VY تشتمل VE CDR1 على تعريف الترتيب رقم: VY تشتمل VL CDR2 على تعريف الترتيب رقم: VE وتشتمل VL CDR3 على تعريف الترتيب رقم: No ¥— الجسم المضاد (antibody) أو الجزء من عنصر الحماية oF حيث يستبدل بصورة تحفظية ما ٠ يصل إلى ثلاثة متخلفات amino acid غير متصلة داخل كل .CDR ¢— الجسم المضاد (antibody) أو الجزء من عنصر الحماية ١ حيث تشتمل منطقة الإطار الرابعة (FR4) (fourth framework region) من منطقة VH المذكورة على ١١16-٠5 acids 800100 من تعريف الترتيب رقم: 4 4. Yo (yooAY — — —o الجسم المضاد (antibody) أو الجزء من عنصر الحماية ١ حيث تشتمل المنطقة VL المذكورة على glycine عند موقع amino acid المقابل للمتخلف رقم ٠٠١ من تعريف الترتيب رقم: 1 (موقع ٠٠١ Kabat يفSARE 1 ب : ل الم“طفاقات 8 21111116 متنطفهة VH) a jis Ah { جتنم ماد د GDE-§ ww ow . ف | قا “© rT و عام rr Yep Ef TR Er (تعزي د a نيب ركم: 1) د الوق ب لقا الحم فقا 1 ارم 7065 جز لارنج واي قات ترا لقا 1 Murine WH ب الال ا ال المي سس i 3 لا Wn SEV لات ل i pad) التركيب رتي ١١ 530155097063515 OPT RSSYBMSWNVECR 15 (TY تمع = الا ب : PEs I Le WAL Lainie a ER sre = gl (تعريف الترثيب رقم: 0 0 Humanized VHD | EVQLLESGGELVOPEESLRLBCAASGTTFSSYAMENVROA &x Ce Ct . : + ب من oe Pore ب J Co اتات لاج سد فانط ليا MEY 1 Lov الخاضايك 1434311647833 (تعريف = شي ثيب رقم Humandzed VED 9 EVQLLESGEELVRPCEALRLECAAS GIT SSYAMEWVROA Ee { ve LHS EA 5 old a ًُ 1106011 By yay الترثيب ,48 1%( Hummegsloed VEZ EVQLIESGRELVQEGUELRLSCARSGIT RE EYAMERVECA ty Ee NE aig ا ب 1 Saat باد ا ني الال 1 ESL Ee vig )3 يف SE ١ رقم Humanized VHI 3 EVQLLESGUCELVORCES LRLECAASEITFESYAMBRVROA & + { TAC م لأ اث الي SERN TERT YAIR NK 4 i ,~ لجح يم دا ا - ا 0 :8 (العريف VE4 ١ 210269370908597 to (¥» 8, wil J يسمعتصمس0ة TE 1 ل م hii a tila puis } Aoi AR Fd 2X ee net ye ot TI pes wo y (تحريف الترثيب رقم $¢ (VY اوعض يرمق Humariced VES) 8 VOLLESGORLVQPEESIRLSDARSUP EPS SO 3 XL JUBRT ROH Vet SR . امال ا 131 لا FERRET اله كيب oo, " تعر يف التركيب LETT ARTNARNTLY A EE 1 زايد vi رقم : £ Morin VH ££) PEHRLEWVATISSCOSVISYPDSVRERETISPRUNARNTLY A: A 0 Su = | wid و أ ان الوا EY WOH عه يون جاه جيه جح جر وحم جح هده بحر يحي حا يا ا . RLS 1 AAA ا الا 1 زيف 0 ديب ركم pE~ati $Y POHGLEWVSAISCSGUSTYYADSVRGRITISRINIRRTLY A { AR :8 1 لهبب؟ 1 اديع يت OT : الما مجه عم وه حا ما 7 A t] اح ّ ا ا 7 يا 0 fy 755710115 Ar ) y oo har قفتت Humanized oe it p 1] م حيار تاج حا جا REET موا يحو مج جو عر اي يي يس اجيس اح حجن و py = oy مان بن I EEX BER 2 حر يقسة VHL $Y PEEGLEWVITISSCRSYISYPRSVEGRFTISRUDNERNILY Ao 4 pA jy ممص مسا (تعر lll (iy قب رقم RETISRONSERRTILY As {Wh & 3 0 ادي ا الصا ) : يكس 0 غيب رقم 0 Gumandzed VEZ 4١ FORGLEWVEAISGSGGSTYYADSVRGRETIERONSRRNTLY oo CT a " يه جعي وو جد TT بين لمح اجاج ام جه اجاج جا و اا لعل ل ا م مال الالح (تعريف A ثيب رقم Humanized VH3 $Y) PONGLEWVSAISSSGOYTYYADSVEGEFTISRONSKNTLY Av (VA 1 ٍ إ ا ا ال ب nnn RnR nnn nnn ET TAT TIN SRNL مج دبي جو + بيه ديد Jat SO Sal PAA ا Sel :114547 (تعريف ار تيب رقي Homenized VEE £) PORGLEWVSTISSGGSYTSYPDSVKGRFTISRONGENTLY Ar (Vi \ ألا BET WT TI CRT SVE A ——————— سيت سس رس SARS ai SEINE ضما REALS BR 4 (تعريف الترتيب رقي Humanized VES §) POHGLEWVITISSSGSYTSYFDSVRGRITISRONSKNTLY Ax (VY ofan ae VO ANRC N wo . Re 7 -١ . Shi 1} بد يكرا ا رج ا ا حي جا (تعريف الترثيب PT (Teh 70007و ريج ا جسم نج لاطا عاسو VH موا M a WV AY Ls PEEUTAMY YD " 8 يف الت ثيب رقب Myrinas VH AY LOMISLESEUTAMY YO 8 0 or عر > (is pi a 0 متم د لتقا مقتنا طال لانيل AY 7ع hb io yo 2 جني ليت وااو تن لاخر مودي yg 4 3 2 قم Humanized VEG AY LUMNSLRARDTAVYYCARQDYRMEYWOOCTLVIVES ARS (تعريف Aumanlzed VED A LUMNELRAE ME he LL TV oe ve i محر Les sl | a] : 0 0ت تتا اتا الم Humanized VEL fue att Tine valk dal MUNG LenS ) ee a . Pa, (تعريف الترثيب Humanizsd VEZ AY LOMNSLRAEDTAVYYCAKQDYAMNYWAOGTLVIVES IT (Vad SRG oe Re م RAE Vad ! ANAND LL Lo LV] “ PETE A di} ed) ثيب رقم A { ET 155 لامر اناي يات ابام لون كاب warrleed VEE AY LOMMILTRAEDTRVYY ESO. Vay Bali Ba Lek d Se Se a Mra ~ لي (تعريف الترتيب رقم: Humanized VHA AY LOMNSLRABDTAVYYOAKODYARFDIWGOGTLUTVSS MY ١ ل ْ: 1 Los و ا ود ل JENA ند امد م اك ا مدي اك 4414 (تعريف الترثيب رقم: ؟7) ١١٠١ يي أ VEE AY امم لصفصوة ا 8 شكل ١(أ) tyoo_ A اج Sil AA aia daa Adley TIE " § مح 0 * ات م 1 iy ل ©200111 منطكة كفيكة متغيرة Mids Lo _ جسم اك } = DORE $ 60 يف لثر تيب رقم ! ما ادن 0 ا ل ج توا ا قلات للم كتثونا ال ترا fa YY يفأ الثرة يبا رقم: may JTEMTOSHEEMETEVGIRVS ITC ب 2 د i رتيب رقم ااا : ion oi PLE 8 ا ا الابنت الاق i wp fs {EV لبا ركم 8 Al Sy 3) IN ١ DIME PES LO ASVIDEVIT - wre a SN RO SERA JGIRVT ITCKASODVETAVAR Y QF : { ١ ريف الثر ثيب رقم: 1 soma LR EAE, Q STOO RE 8 EA TE . 3) Humanized vLg لايديا = FAS LIASVEDRVT ITC RASGDVSTRVAN Y بون DA by نعر 2 يب رقم 1131311 كات 8 4 TOMTOG EES LIAS VERDE TAT eon i" ey فا : ل Cain 8 8 8 ا سق 7م وت انا ل بنقناي لات قا os Tr Ea 0" 4 الترتيب رقم: dy pay BamsniE I 4 TOMI OE RES LS ASVGRENT + Hyd يف الثرة ٍ: ّ' 4 ع هه توصي nV pi تع ل CORE fe RR SE EE) ب للب ما 610 LEE ا اجر لوديا at t : م ا a ف اله !' Humanized قتا ١ EDP TITCRASQSTSTALNSIOONE 46 (¥) (تعريف الترتيب رقم: اجر ب" مال 11ل 4 ١ 57070537 : ل 1 : EE 1 0 ب 0 517007705031578 55353 بس Hy mani sad Wns od DIOMTOERESLEAS 1 3 | 0" 3 )! اكات ار اليا ا EB 1 مضع حت حصي دمج As ل ب ينبا رقم 1 7101315377077 3570 x ب ل ليلب كم : = f AS PHILLY SASYRYTGVPRRI TGS GAG . 101 ل No 0 ¥ يبا ارقم A dd 4) De EAE ER ANAAAAAAAS واي أ TO FE TR YT و PERLOP Y 3 = ف ٍّ ا اال #ْ 0 ESE ثرا اللا ادح احا ا 35 : oP NE ع ال يب رق SHALL $Y GRABPRLLIY D ب 2750508307027 SOLAR قم 47 د ly omar : 8 1 RY ا ل 0 res Ja Ne 1 3 PR ب ها الثر كيب 1) SSS SI ال 5 ل م A (1 7 ب رقم: igh (تعريف 3 TE جوج اي A 4 SEAPKIITIYES eR ١ 50323370777 رو Ace ف الترتيب رقم: ا ا Cras LIVABSSLQEGVESRFRGEGRATLVTLTY a 8 يب رقم ل “a : تم SAAN 9 0 ل LR CSCTDETLEISSNLON (13 يف الترة قم: Humanized اتا YY Gras. oe 531773275530711 35 م vy تعريف ل ب و 1 ا و2 قت £Y GEAPE: Sd SASSLY Lod PER 705050701777 A { =F كيب Humanized VIE x ل + 1 ا 77130505070 SL ian 1 A Wid oh GHAPKLLINAAREIRSG VER تعر يفا ليلب ال ا Rumanized Vid iY معاي YSRSSLOSGVPARESCEGIEIDET 0 |ّ 8 EE لخ 2% LSE NLL ض اها Humanized VLE 1 GEA 0 1 0 y re 1 1 الثرة + ليت ا ا THLE IK io 4 iy ws of ry 5 i Boars 5 71 ١ (تعريف الترتيب رقم 45 ؟ 5 ْ' . 5 ) 0 0 ER : : ~ 0 CRONE 8 8 مير oes a a PITH VE TE 3 Lo 3 الث ركيب زقم: Lo] } ل he HOEATY YCQUNY STRWE FAG TIVE i.Ya A Cacia Humanized VLD ral 3 Had i pa ب a ire > 5 ! 5 0 ِ 0 ٍ 3 معد تج عضي VL AY 7 ةي Bi NETS 5 a - BOFATYYCQQORYSTPRT FERETRVELR yay (0 No an od Humanized VLE AY HUPATYYCQQH OSYSTRWT FOGETHVETE yoy {VY الث تيب رهم a Oc oan A وا ل أ ارط يط © BRIN ين 5 ¥ ا اال Reet | جو ب : + جب 9D ا اي جم اهم شرج نل بض شاط را ٍ ; ra . ES 1 ١ 50 7ل م Ye ¥ (vy دريف اندر نيبا رقم: ( ال ا ا ال ار ا 5 BN SERA Fumagized Vi4 Al ED ens NV FOGOTRVELE Hn ; ed WLI AY ااا Anmanized VLE \ Hig 0 (ب) ١ شكل ههباو مثال مقارن —_— جسم مضاد 15000 gq 7 ; | - - | ال | ]1 - | مم | | “ad 4 | | I. | -ME. GAS QUAD شكل ؟() ده_ A 7 _ X Li 3 3 Yo NE اا ve | Ly 2 | Lo © ٍ is by FT a : : م ب _ ا" ; ] : ji ْ كاحي كي يرل الا اا a مر ف ا ال .أ | NN سس , 8 ع ٍْ : إْ TT | إ ا ا | 00 ب 3 | | Egy 7%, { | Hy | : 3 00 ٍ رص رس رص رك رك ا 5 Lo | Lo E © | 5 o- | | : ٍّْ | : 3 © ض + | NNN { | : : PN : © | | | ال : : : : ابا Bn الو hy ب : 1 : ٍ ; Par الالح خخ 00 | | oy IRN ٍ : ْ ' م : ER § 3 1 ا : Fa irs a | 1 SO, ES n,n : TER | SEP Don GA 5 QUAD EDL. شكل ؟(ب) tyooSora 3 ood rT اا | lL ا ض | ووم 5 [] | | 92 : | | 5 ال ؤ | hovel a | | | 21 ا | | | 32 ااا | | =EE. RU | هه EE 7 0 م م ا نم م صفر a A A 3 > . مثال مقارن I< ; ب دهامل Quad 1 oe TO — _ I : : 3 = ليا ٍ YY. ! = ! ] I ٠# 4 YA | 1 Gastroc ا a 0 ل عر ل em سل اي ض i vi ض Vid Yo» Yo Ye حا ل 3 صفر الجر ic (مجم/ كجم شكل 4() م0=« 4— YE AYA : 9 Q a Quad 2 - | 3 PORN 08 3 3 - بال Ro 7 Thee 2.0 : 0 جا + ! 72 ba] ب "م سمب انيم دا } i د “r ا لا j : 3 > د Re oe 1 را إْ 4 ا MP - بس 1 إْ REE.Gastroc © 4 ; ' 3 2 : زا 1d 4 ا 2 Be 3 د Ya | 0 5 + Ys . 2 الجرعة (مجم/ كجم) شكل ؛ (ب) دهداك , 0 el ني 1 ih ا ا 1 اا ل . ٍْ ّآ gw 5 8 i 2 8 / i Se TTH LEE Rnd وى HEHE ).1 Blk ERIE.FY | | ل BITE ل الام 1101 قم > و 2 HT = H الال 1 i 7 ; ناويا > RS AE | 1 لي صفر JUEEE {TERE TERS TERE TIRE TAS fama Xs كجم Jana ¥ PENS Jana Ys كجم Jans ١ كجم ال {pe كجم ومنط Js شكل (ije ارq \ — _ v y ض 3 2 w— [2 ءا" اط ١ لي © ل - 3 م | | ا | 5 Co | I a = ١ EE م ١ | ب 3 NN | | + ب RY | | BEY 31 ١ T FT 3 ا | | CORY | = مضلا | | ORY كي ل N | : a _ ] ْ بأ ا اننا الا 1 مو ل ِْ | N | ٍْ ا ام ا | | لنب ا ) ال ا 8 اس لشل_ل لل[ لد لل تل صنت + 2 + ~ ة 31 1 01 : أ 46 ا ا 2 ا 1 1 1 Sr = ب I< > )=( دهYY)- .. 8 — ا 3 © 1-1 900 ا 4 = 335 8 شكل ١(أ) el Ys } \ و8 ' ed 09 > | | ض لا 8 7 3 | . ا | 2 ١١١ ب ْ ييا | J Vol شدخ مضاد وسط ناقل شكل +(ب) ههCe وسط ناقل [TT] © جسم مضاد Ya — 1] ل MDX MDX نا 7576و 5 GAS QUAD GAS QUAD ()y شكل هه_ q أ _ Cg Yin 1 BIAS الثمم كل ارا ا ار كرك وم ECE LA IAF SETS EE LPI Pe § et Fy i Fe yo Ye 3 ا فاق Soe TR ay 8 Ee § ا أ ا ey "م ال لغ 1 را ب ْ [ate ع حال ا ال قا SER 7 | و لم7 iA ا ¥ : + \ La ; : ل fs . SX x , اا < i 8 3 « ERA to or oe . " Le ل.ع ْ LY YE LA ا LT ل [ AN Sede Je Fowl قل .77 .لل armed 23 ٍْ Pomme Maldon ا ا اح va | با لتر حا د التو اميا : ; Cop LAT اند ف اننا BL ee 0 A ed جرع م ل ا حر bool لح +3 A LER SER LEST IE MNCL Nb ا 2 7 rT 7 ا ب ٍ Sh a ACH TIE DEAE ٍْ ولق رعق الى EEE DEERE * 0 لمكا 4 i AEE Eh ل وخ الراك و > م [ الم قا CORE MET of BEE JA REESE SI ES Ba Fr Fe ا دالا الك لات .انك 3< وال 4 1 . ٍِْ ً م 3 ع + عل م ب : | Sr SA : EE : SR DEER of ا انان CR $ : i a w TEN : fy Ale ald 1 ل - 8 = VEGAN Le ا الا -١ 3 ارد 7ر7 Fo aga. & E 3 xR ® مدا 7" اياك . صر 8 : ال ل 7 2 بغ to. ° N 2 “= LY ل م ل ليق أ ل دارج PEE 1 | | TVS +1 اي TE SAE UE EE PEA va] | Fela SACRA انا لتنا رق oT ال RR ig gE .ادج ال ا ما 3 7 A EEE EE ا ان لين ل ال ال | جم NE 3 مره ٍْ ا FEL اانا جا خأ يد اننا 0 1 كم اد ا ا + J ا ا كم مم ل ب" £3 اي ب 0 , 0 :ٍ X cer ra 1 يُ حب Sr WA 1 E اب 0 owl . عات 7 : ْ ار اح / ارق TOA | TEE RI RI 3 ا اين اام م 1 3 7 و oF 3" “a * = « 0% A 3 ARE IRS Ey a &s 5 Ts 8 رج لاف ون DAEs SY ا الاي" كد آل ْ Hor « ب اراي أ oo : ب : >“ ٍ > 1 0 1 > : :8 1 ٍ م (yoo]7[ إجمالي كتلة اللحم EE كتلة لحم الساق vy | Ye 3 ب ٍ 0 0 , 3 mim _ . 1 ee ee 1 5 0 ا ا - 3 EEE | 1 ل اال nl ٠١ aS aa مجم/كجم ؟ مجم/ كجم وسط ناقل شكل A ههما ااا ge ا , 3 ٠ Ca ؟ T PF aan pas fan 4 ع" ِ 3 * 3 5 gs و fol Jana 3 ٠ كجم " 1 — mee لك V4 Pe, wo wy = Q om) ¥ م يود بيد ب : ب حي &F Fé ". uy 20a 1 hos $ A VY ie! Ye. 3 J لأسابيعشكل. 5 ههYam 2 ا + | ا pe . =] ILI Ta 3 | 7 اا ا اي ْ ب بل ْ : yy اا ب ; lids a ا رس كر ررب سام ا ّ دة ْ oe ا وي Vn ا ا ا م ا ل صفر ed سم A gts =. . a * . g k - 7 A Jal مجم/ كجم وسط Ys FERS / سجح Ya )(٠١ شكل 0ه— \ a= x * 0 = Yoo . 9 ا ا | لا 1 Veo . =] v7. RN 4 Vo ا 1 0| سسا لسن + ٍ VSS ..__ i 3 gL LAS 5 0 | g A و § Ca ْ اا رح رسك رص كرا ay 0 ey Dome i Tar FS ES 0 م ام ا 0 0 ا من م ا وا ا رس رح درك تم كر در ood EEE : SSE Da Joon i I NN se ل[. 0 ; : مجم/ كجم وسط ناقل ٠ مجم/ كجم ؟٠ )ب(٠١ شكل 0ه_ \ ٠ \ —_... .. ... ..a. LL ا ل د ا الل اسن د اا ا لأسا ا Lae ENN =. a اا ا ل ا ا اي اق اا as ee. - ااا A TN ae NR ا Na a ا ال F cea - = aa . . > La laa La . a ma aaa meee . aa ...__ a=... .. SEE I tyoo_ \ ٠ \ —_ VHO VH منطقة Jodi {2A (تعريف الترثيبا رقم: GDF-8 جسم مضاد ضد OGD1.0.0 سلسلة ثقيلة تابتو7ا2 3295 LVOPECSLRL عا و2 ماما SYAMSWVROA . 201613737 1355065718: PRSVECEFTT SRONSENTLY LOMNSLRARD TAVYYCAKOD YAMNYWEQGT LVIVISASTK حك GESVFPRLAPS SNSTSGUTAA اطع له لاس تا BPVTVIWNSE ALTSCVHTIEP AVIQSSCLYHE YA. LIESVYTVESS SLOTOTY ION VWNHKPSNTRY DEHVEPKESCD ممعم تر PEARGAPEVE Yi LEPPRERDTL MISRTRPEVTC VVVDVEHEDP EVEFNWYVDE VEVANAKTEE REROYNSTYHE Yoo VYSVLOVLED DWLNGREVHO KVSNKALPAP IERTISKARG QPRERQVYTL PRIREEMIKN v1. تنمتو تقل PYPSDIAVEW ESNGOPENNY KTTPPVLDEDR GSTFLYSKLT VOKSRWQOGN ا VESCAVMHEA LENIYIURSL SLSPGK (hy Ks171.0 VE (تعريف الترثيب رقم: 0%( تشمل منطقة GDF-8 aus خفيفة 5131.0.0©© جنم مضاد Sl 01005055 LEASVCEDRVT ITCKASODVS مسوو ابد CRAPKLLIYS ASYRYTGVES 1. RFSGEEGEEETD PILTISSLOP BDFATYYCOQ HYSTPRTPGE GYRVEIKETV AARSVIIFER ملا SOEQLKSETA SVVCLLNNFY PREAKVOWKY DNALOSONSQ معممموع ضوع STYALSITLT YA. LEKADYEKHK قوت لتعملا LASPVTHSPN ROEC (SY شكل ههمدة سريان هذه البراءة عشرون سنة من تاريخ إيداع الطلب وذلك بشرط تسديد المقابل المالي السنوي للبراءة وعدم بطلانها أو سقوطها لمخالفتها لأي من أحكام نظام براءات الاختراع والتصميمات التخطيطية للدارات المتكاملة والأصناف النباتية والنماذج الصناعية أو لائحته التنفيذية صادرة عن مدينة الملك عبدالعزيز للعلوم والتقنية ؛ مكتب البراءات السعودي ص ب TAT الرياض 57؟؟١١ ¢ المملكة العربية السعودية بريد الكتروني: patents @kacst.edu.sa
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660232P | 2012-06-15 | 2012-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA113340642B1 true SA113340642B1 (ar) | 2015-09-15 |
Family
ID=48914383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA113340642A SA113340642B1 (ar) | 2012-06-15 | 2013-06-12 | أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8992913B2 (ar) |
| EP (1) | EP2861617A1 (ar) |
| JP (3) | JP6433889B2 (ar) |
| KR (1) | KR101704893B1 (ar) |
| CN (1) | CN104487453B (ar) |
| AR (1) | AR093217A1 (ar) |
| AU (1) | AU2013276131B2 (ar) |
| CA (1) | CA2876397C (ar) |
| CO (1) | CO7151524A2 (ar) |
| HK (1) | HK1208471A1 (ar) |
| IL (1) | IL236289A0 (ar) |
| MX (1) | MX364738B (ar) |
| MY (1) | MY177331A (ar) |
| NZ (1) | NZ702269A (ar) |
| PE (1) | PE20150223A1 (ar) |
| PH (1) | PH12014502698B1 (ar) |
| RU (1) | RU2630634C2 (ar) |
| SA (1) | SA113340642B1 (ar) |
| SG (1) | SG11201408042YA (ar) |
| TW (1) | TWI495643B (ar) |
| WO (1) | WO2013186719A1 (ar) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
| PL2275443T3 (pl) | 2008-04-11 | 2016-05-31 | Chugai Pharmaceutical Co Ltd | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| ES2663946T3 (es) | 2011-11-14 | 2018-04-17 | Regeneron Pharmaceuticals, Inc. | Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A |
| EP2861617A1 (en) * | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
| PE20150954A1 (es) | 2012-09-13 | 2015-06-20 | Bristol Myers Squibb Co | Proteinas del dominio de soporte basadas en fibronectina que se fijan a miostatina |
| JP6475639B2 (ja) | 2013-01-25 | 2019-02-27 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| IL301607A (en) | 2013-05-06 | 2023-05-01 | Scholar Rock Inc | Preparations and methods for growth factor modulation |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| EP3450557A1 (en) * | 2013-12-25 | 2019-03-06 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
| JP6706617B2 (ja) | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| KR102650420B1 (ko) | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| CN104829728B (zh) * | 2015-01-21 | 2019-03-12 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体her2xcd3的构建及应用 |
| US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
| MA41867A (fr) * | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
| EP3283519A1 (en) * | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| CN113896789A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| SG11201805709RA (en) * | 2016-01-08 | 2018-07-30 | Scholar Rock Inc | Anti-pro/latent myostatin antibodies and methods of use thereof |
| EP3432927A4 (en) | 2016-03-24 | 2019-11-20 | Gensun Biopharma Inc. | TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT |
| ES2830440T3 (es) | 2016-06-13 | 2021-06-03 | Scholar Rock Inc | Uso de inhibidores de miostatina y terapias combinadas |
| CA2971303A1 (en) | 2016-06-21 | 2017-12-21 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8 |
| CN110062885A (zh) | 2016-11-01 | 2019-07-26 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白3（tim-3）的抗体 |
| CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
| JP7198757B2 (ja) | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
| AU2018205401A1 (en) | 2017-01-09 | 2019-07-25 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| WO2018156711A1 (en) * | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Il13ra2-binding chimeric antigen receptors |
| KR20200128125A (ko) | 2018-03-01 | 2020-11-11 | 리제너론 파아마슈티컬스, 인크. | 신체 조성을 변경하기 위한 방법 |
| CN110540590B (zh) * | 2018-05-29 | 2023-08-18 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制物的开发和应用 |
| CN112739717A (zh) | 2018-06-29 | 2021-04-30 | 璟尚生物制药公司 | 三特异性拮抗剂 |
| EP3990030A1 (en) | 2019-06-27 | 2022-05-04 | Pfizer Inc. | Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy |
| WO2020263312A1 (en) | 2019-06-28 | 2020-12-30 | Gensun Biopharma, Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| WO2022087458A1 (en) * | 2020-10-23 | 2022-04-28 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2023196957A2 (en) * | 2022-04-08 | 2023-10-12 | The Wistar Institute Of Anatomy And Biology | Bispecific t cell engagers targeting tumor antigens |
| US20240199728A1 (en) * | 2022-09-21 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| DE69034007T2 (de) | 1989-04-28 | 2003-05-08 | Riker Laboratories Inc., Northridge | Inhalationsvorrichtung für Trockenpulver |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| JP3801196B2 (ja) | 1993-03-09 | 2006-07-26 | ジェンザイム・コーポレイション | 乳からの対象化合物の単離 |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US20030074680A1 (en) | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6673534B1 (en) | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| SE9502800D0 (sv) | 1995-08-10 | 1995-08-10 | Astra Ab | Disposable inhaler |
| JP2000500120A (ja) | 1995-09-21 | 2000-01-11 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | ポリ（エチレングリコール）と抗グルタミン酸デカルボキシラーゼ抗体の結合体の膵島細胞指向ターゲット化 |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| PT2045322E (pt) | 1997-07-14 | 2015-10-16 | Université de Liège | Musculatura dupla em mamíferos |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| EP1015468A4 (en) | 1997-08-29 | 2000-09-06 | Human Genome Sciences Inc | FOLLISTATINE-3 |
| WO1999024618A1 (en) | 1997-11-10 | 1999-05-20 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| CA2319703C (en) | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| CA2331410C (en) | 1998-05-06 | 2009-07-14 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| BR0008188A (pt) | 1999-01-21 | 2002-02-13 | Metamorphix Inc | Inibidores de fator de diferenciação de crescimento e usos para os mesmos |
| CN1384757A (zh) | 1999-07-20 | 2002-12-11 | 法麦克萨有限公司 | 下调gdf－8活性的方法 |
| AU1097301A (en) * | 1999-10-22 | 2001-05-08 | Scripps Research Institute, The | Humanization of non-human, mammalian antibodies |
| US7037501B2 (en) | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| AU2003217612A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| US20040110933A1 (en) * | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| KR20060026860A (ko) * | 2003-06-02 | 2006-03-24 | 와이어쓰 | 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도 |
| AU2005227896B2 (en) * | 2004-03-23 | 2008-11-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2006031653A2 (en) * | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
| MX2007011400A (es) | 2005-03-23 | 2007-10-11 | Wyeth Corp | Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8). |
| EP1864139A2 (en) | 2005-03-23 | 2007-12-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
| EA201100642A1 (ru) * | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| JP5415071B2 (ja) | 2005-08-19 | 2014-02-12 | ワイス・エルエルシー | Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用 |
| JP2010508043A (ja) * | 2006-10-31 | 2010-03-18 | イミュノジェン・インコーポレーテッド | 抗体産生を改善するための方法 |
| PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| EP2861617A1 (en) * | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
-
2013
- 2013-06-12 EP EP13744828.8A patent/EP2861617A1/en not_active Withdrawn
- 2013-06-12 SA SA113340642A patent/SA113340642B1/ar unknown
- 2013-06-12 AU AU2013276131A patent/AU2013276131B2/en not_active Ceased
- 2013-06-12 PE PE2014002435A patent/PE20150223A1/es active IP Right Grant
- 2013-06-12 NZ NZ702269A patent/NZ702269A/en not_active IP Right Cessation
- 2013-06-12 MY MYPI2014703762A patent/MY177331A/en unknown
- 2013-06-12 KR KR1020147034989A patent/KR101704893B1/ko active IP Right Grant
- 2013-06-12 MX MX2014014995A patent/MX364738B/es active IP Right Grant
- 2013-06-12 CN CN201380030753.0A patent/CN104487453B/zh not_active Expired - Fee Related
- 2013-06-12 JP JP2015516728A patent/JP6433889B2/ja not_active Expired - Fee Related
- 2013-06-12 CA CA2876397A patent/CA2876397C/en not_active Expired - Fee Related
- 2013-06-12 WO PCT/IB2013/054810 patent/WO2013186719A1/en active Application Filing
- 2013-06-12 SG SG11201408042YA patent/SG11201408042YA/en unknown
- 2013-06-12 US US13/916,379 patent/US8992913B2/en not_active Expired - Fee Related
- 2013-06-12 RU RU2014150433A patent/RU2630634C2/ru active
- 2013-06-14 AR ARP130102122A patent/AR093217A1/es unknown
- 2013-06-14 TW TW102121200A patent/TWI495643B/zh not_active IP Right Cessation
-
2014
- 2014-11-27 CO CO14261553A patent/CO7151524A2/es unknown
- 2014-12-03 PH PH12014502698A patent/PH12014502698B1/en unknown
- 2014-12-15 IL IL236289A patent/IL236289A0/en active IP Right Grant
-
2015
- 2015-02-19 US US14/626,321 patent/US9751937B2/en active Active
- 2015-09-11 HK HK15108889.0A patent/HK1208471A1/xx not_active IP Right Cessation
-
2017
- 2017-08-01 US US15/666,317 patent/US20180057579A1/en not_active Abandoned
-
2018
- 2018-11-07 JP JP2018209932A patent/JP2019059738A/ja active Pending
-
2019
- 2019-11-13 US US16/682,437 patent/US20200277365A1/en not_active Abandoned
-
2020
- 2020-07-21 JP JP2020124373A patent/JP2021001170A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA113340642B1 (ar) | أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها | |
| MX2020007842A (es) | Anticuerpos anti-pd-l1 y usos de los mismos. | |
| MX2011010027A (es) | Anticuerpos solubles "solo de cadena pesada". | |
| WO2011150336A3 (en) | System and method for electronic policyholder review using dynamic interviews | |
| CY1121950T1 (el) | Νεα αντισωματα εναντι φωσφορυλχολινης | |
| MX2020008489A (es) | Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades. | |
| NZ600915A (en) | Humanised antibodies with anti-tumour activity | |
| Fu et al. | A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike | |
| NZ702282A (en) | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease | |
| Gandour | Forest Wars: A Trilogy on Combating Deforestation in the Brazilian Amazon | |
| Wang et al. | Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants | |
| Sano et al. | Strengthening EIA in Asia | |
| CHOTTE et al. | Land degradation | |
| Centers for Medicare & Medicaid Services (CMS), HHS | Medicare Program; Inpatient Psychiatric Facilities Prospective Payment System--Update for Fiscal Year Beginning October 1, 2015 (FY 2016). Final rule | |
| Heisig | OLR clears Happ | |
| McPhedran et al. | Quantifying homicide trends in Australia: a methodological caution | |
| Naigles et al. | Flexibility in early verb use: Evidence from a multiple-N dairy study: III. A general description of early verb growth and use. | |
| Rubio-Misas et al. | Determinants of Mergers and Acquisitions: Evidence from the Spanish Insurance Industry | |
| Gorte et al. | Climate Change and International Deforestation: Legislative Analysis | |
| Milosevic et al. | Economic Security Indicators-the Environment to the Republic of Serbia | |
| Ćulafić | Essential questions of the concept of corporate social responsibility | |
| Kim | Dynamics of the Korea-EU FTA: From the early stage to the entry-into-force | |
| Etinski | Equalization of International Protection of Economic, Social and Cultural Rights with International Protection of Civil and Political Rights | |
| Chartin et al. | Estimating Soil Organic Carbon stocks and uncertainties for the National inventory Report-a study case in Southern Belgium | |
| Chriqui et al. | Stakeholder perspectives and lessons learned in the (failed) implementation of the Cook County, Illinois, Sweetened Beverage Tax |